Japan - japansk - すりの適正使用協議会 RAD-AR Council, Japan

ノバルティス ファーマ株式会社 - バルサルタン - 白色の錠剤、直径7.1mm、厚さ2.8mm - 体内で産生されるアンジオテンシンii受容体に結合し、昇圧作用を示すアンジオテンシンiiの血管収縮作用を遮断し、高血圧症の血圧を下げます。
通常、高血圧症の治療に用いられます。

Japan - engelsk - すりの適正使用協議会 RAD-AR Council, Japan

novartis pharma k.k. - valsartan - white tablet, diameter: 7.1 mm, thickness: 2.8 mm

Malta - engelsk - Medicines Authority

novartis pharmaceuticals uk limited - hydrochlorothiazide; valsartan - film-coated tablet - hydrochlorothiazide 12.5 mg; valsartan 80 mg - agents acting on the renin-angiotensin system

Malta - engelsk - Medicines Authority

novartis pharmaceuticals uk limited - hydrochlorothiazide; valsartan - film-coated tablet - hydrochlorothiazide 12.5 mg; valsartan 160 mg - agents acting on the renin-angiotensin system

Malta - engelsk - Medicines Authority

novartis pharmaceuticals uk limited - hydrochlorothiazide; valsartan - film-coated tablet - hydrochlorothiazide 25 mg; valsartan 160 mg - agents acting on the renin-angiotensin system

Malta - engelsk - Medicines Authority

novartis pharmaceuticals uk limited - hydrochlorothiazide; valsartan - film-coated tablet - hydrochlorothiazide 12.5 mg; valsartan 320 mg - agents acting on the renin-angiotensin system

Malta - engelsk - Medicines Authority

novartis pharmaceuticals uk limited - hydrochlorothiazide; valsartan - film-coated tablet - hydrochlorothiazide 25 mg; valsartan 320 mg - agents acting on the renin-angiotensin system

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - valsartan 80 mg - diovan hct (valsartan and hydrochlorothiazide, usp) is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the arb class to which valsartan principally belongs. there are no controlled trials demonstrating risk reduction with diovan hct. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national comm

Irland - engelsk - HPRA (Health Products Regulatory Authority)

novartis ireland limited - valsartan - film-coated tablet - 80 milligram(s) - angiotensin ii antagonists, plain; valsartan

Irland - engelsk - HPRA (Health Products Regulatory Authority)

novartis ireland limited - valsartan - film-coated tablet - 160 milligram(s) - angiotensin ii antagonists, plain; valsartan